Welcome to our dedicated page for Bridgebio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BridgeBio Pharma, Inc. (NASDAQ: BBIO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. BridgeBio is a biopharmaceutical company focused on medicines for genetic diseases, and its filings give detailed insight into clinical milestones, financial condition, capital structure, and corporate governance.
Current reports on Form 8-K are a key source of information for BBIO. The company uses 8-K filings to report material events such as positive Phase 3 topline results for encaleret in autosomal dominant hypocalcemia type 1 and for BBP-418 in LGMD2I/R9, quarterly business updates and financial results, and significant agreements like royalty interest purchase and sale arrangements tied to acoramidis royalties in Europe. 8-Ks also describe shareholder votes on amendments to the certificate of incorporation, stock incentive plans, and other governance matters.
Investors can also review filings that discuss BridgeBio’s financing activities, including proposed offerings of convertible senior notes and the terms, ranking, and convertibility features of such instruments, as well as transactions that monetize future royalty streams. These documents help explain how the company funds commercialization of Attruby (acoramidis) and its broader development pipeline.
On Stock Titan, BBIO filings are updated as new documents are posted to EDGAR. AI-powered summaries highlight the main points of long forms such as 8-Ks, so readers can quickly see why a filing was made, what agreements or results were disclosed, and how it may relate to BridgeBio’s clinical programs, ATTR-CM franchise, or capital structure. Users can drill down into individual filings for full legal and financial detail, including exhibits referenced in the company’s reports.
BridgeBio Pharma Director Ali J. Satvat reported two significant equity transactions on June 20, 2025:
- Received 6,589 restricted stock units (RSUs) at $0, bringing total direct ownership to 165,993 shares. RSUs vest over three years through June 20, 2028
- Granted stock options to purchase 8,425 shares at an exercise price of $41.73 per share, expiring June 19, 2035
Both grants are subject to continued service on the board and follow a three-year vesting schedule, with one-third vesting each year starting June 20, 2025. The transactions were executed under the company's 2021 Amended and Restated Stock Option and Incentive Plan. Satvat serves as a Director but is not a 10% owner of BridgeBio Pharma.
BridgeBio Pharma director Charles J. Homcy received new equity compensation grants on June 20, 2025, consisting of:
- 6,589 Restricted Stock Units (RSUs) with a $0 exercise price, vesting over 3 years through June 20, 2028
- 8,425 Stock Options with an exercise price of $41.73, vesting over 3 years through June 20, 2028
Following these transactions, Homcy directly owns 1,236,674 shares of common stock. Both the RSUs and stock options are subject to continued service on BridgeBio's board of directors. The grants were made under the company's 2021 Amended and Restated Stock Option and Incentive Plan. This Form 4 filing represents standard board member equity compensation.
BridgeBio Pharma Director Fred Hassan received new equity compensation grants on June 20, 2025, consisting of:
- 6,589 Restricted Stock Units (RSUs) with a $0 exercise price, bringing total direct ownership to 25,889 shares
- 8,425 Stock Options with an exercise price of $41.73 and expiration date of June 19, 2035
Both grants follow a 3-year vesting schedule with one-third vesting each year starting June 20, 2025, and completing on June 20, 2028. Vesting is contingent on Hassan's continued service as a director. The awards were granted under the company's 2021 Amended and Restated Stock Option and Incentive Plan. This Form 4 filing was signed on June 24, 2025, within the required reporting window.
BridgeBio Pharma Director Douglas A. Dachille reported multiple equity transactions on June 20, 2025:
- Received 6,589 restricted stock units (RSUs) with $0 exercise price, vesting over three years through June 20, 2028
- Granted 8,425 stock options with strike price of $41.73, vesting over three years and expiring June 19, 2035
- Currently holds 20,000 shares indirectly through The Dachille 2012-1 Family Trust for his children's benefit
All equity grants are subject to continued service on BridgeBio's board of directors. The RSUs and options will vest in three equal annual installments starting June 20, 2025. These grants appear to be part of the company's standard director compensation under their 2021 Amended and Restated Stock Option and Incentive Plan.
BridgeBio Pharma Director Hannah Valantine reported multiple equity transactions on June 20, 2025:
- Received 6,589 Restricted Stock Units (RSUs) at $0 cost, vesting over three years through June 20, 2028
- Granted 8,425 stock options with strike price of $41.73, exercisable until June 19, 2035
- Options and RSUs vest in three equal annual installments starting June 20, 2025
Following these transactions, Valantine's holdings include:
- Direct ownership: 8,353 common shares and 8,425 stock options
- Indirect ownership: 3,433 shares held by spouse
These grants appear to be part of standard director compensation under the company's 2021 Amended and Restated Stock Option and Incentive Plan. All vesting is contingent on continued board service.
BridgeBio Pharma Director Randal W. Scott reported significant equity compensation grants on June 20, 2025. The transactions include:
- 6,589 Restricted Stock Units (RSUs) granted at $0, vesting over three years through June 20, 2028
- 8,425 Stock Options awarded with an exercise price of $41.73, vesting over three years through June 20, 2028
Following these transactions, Scott's holdings include 11,589 shares held directly and 4,000 shares held indirectly through Thinking Bench Capital LLC. Both the RSUs and stock options are subject to continued service on the board of directors. The grants were made under the company's 2021 Amended and Restated Stock Option and Incentive Plan, representing standard director compensation arrangements.
BridgeBio Pharma, Inc. (BBIO) – Form 144 notice of proposed sale
This filing informs the SEC of an intended insider sale under Rule 144:
- Securities: Common Stock
- Shares to be sold: 100,000
- Aggregate market value: $4,422,803.30
- Portion of outstanding: ≈0.05% of the 189,880,720 shares outstanding
- Broker: Merrill Lynch, 555 California St, 18th Fl, San Francisco, CA 94104
- Planned sale date: 24 Jun 2025 on Nasdaq
- How acquired: 200,000-share stock bonus received 1 Oct 2021 from BridgeBio Pharma
- No sales by the filer during the past three months.
The signer attests that no undisclosed material adverse information is known. The notice authorises—but does not require—sales within the next 90 days.
BridgeBio Pharma, Inc. filed a Form 8-K reporting corporate documentation updates. The filing lists a Certificate of Amendment to the Amended and Restated Certificate of Incorporation and the Second Amended and Restated 2021 Stock Option and Incentive Plan with form award agreements as exhibits. The cover page identifies the company, ticker (BBIO), Nasdaq listing and corporate contact details. The document includes an interactive data file reference and is signed by the company’s Chief Legal Officer and Secretary.